Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -52.51 M

Immuneering Corporation Free Cash Flow is USD -52.51 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -6.77% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Immuneering Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -49.18 M, a -16.33% change year over year.
Immuneering Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -42.28 M, a -55.72% change year over year.
Immuneering Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -27.15 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years